Sean Esteban McCabe1, Deborah D Kloska2, Philip Veliz3, Justin Jager4, John E Schulenberg5. 1. Substance Abuse Research Center and Institute for Research on Women and Gender, University of Michigan, Ann Arbor, MI, USA. 2. Institute for Social Research, University of Michigan, Ann Arbor, MI, USA. 3. Institute for Research on Women and Gender, University of Michigan, Ann Arbor, MI, USA. 4. T. Denny Sanford School of Social and Family Dynamics, Arizona State University, Tempe, AZ, USA. 5. Institute for Social Research and Department of Psychology, University of Michigan, Ann Arbor, MI, USA.
Abstract
AIMS: To identify the developmental course of non-medical use of four separate prescription drug classes (opioids, sedatives, stimulants and tranquilizers) by examining the general functional growth and related covariates during the transition from adolescence to adulthood in the United States. DESIGN: Nationally representative probability samples of high school seniors were followed longitudinally across five waves (waves 1, 2, 3, 4 and 5: modal ages 18, 19/20, 21/22, 23/24 and 25/26 years, respectively). SETTING: Data were collected via self-administered questionnaires to high school seniors and young adults in the United States. PARTICIPANTS: The sample consisted of nearly 72 000 individuals in 30 cohorts (high school senior years of 1977-2006) who participated in at least one wave. MEASUREMENTS: Self-reports of annual non-medical use of prescription opioids, sedatives, stimulants, and tranquilizers. FINDINGS: The annual non-medical use of prescription opioids, sedatives, stimulants and tranquilizers was highest at wave 1 over the five waves. There was a consistent descending path (linear and quadratic slopes, P < 0.001) in annual non-medical use from baseline across all four prescription drug classes (e.g. opioids linear slope = -0.043 and opioids quadratic slope = 0.034, P < 0.001). While the annual non-medical use of stimulants declined over time (linear slope = 0.063, P < 0.01; quadratic slope = -0.133, P < 0.001), the same decrease was not observed for the annual non-medical use of prescription opioids, sedatives or tranquilizers when controlling for socio-demographic and substance use behaviors at baseline. The covariates associated with the general functional growth differed across the four prescription drug classes. CONCLUSIONS: The non-medical use of prescription opioids, sedatives, stimulants and tranquilizers appears to peak during late adolescence, suggesting preventive intervention efforts should be initiated in early adolescence. The developmental course of non-medical use is not the same among all four classes of prescription drugs, suggesting that each drug class warrants individual research.
AIMS: To identify the developmental course of non-medical use of four separate prescription drug classes (opioids, sedatives, stimulants and tranquilizers) by examining the general functional growth and related covariates during the transition from adolescence to adulthood in the United States. DESIGN: Nationally representative probability samples of high school seniors were followed longitudinally across five waves (waves 1, 2, 3, 4 and 5: modal ages 18, 19/20, 21/22, 23/24 and 25/26 years, respectively). SETTING: Data were collected via self-administered questionnaires to high school seniors and young adults in the United States. PARTICIPANTS: The sample consisted of nearly 72 000 individuals in 30 cohorts (high school senior years of 1977-2006) who participated in at least one wave. MEASUREMENTS: Self-reports of annual non-medical use of prescription opioids, sedatives, stimulants, and tranquilizers. FINDINGS: The annual non-medical use of prescription opioids, sedatives, stimulants and tranquilizers was highest at wave 1 over the five waves. There was a consistent descending path (linear and quadratic slopes, P < 0.001) in annual non-medical use from baseline across all four prescription drug classes (e.g. opioids linear slope = -0.043 and opioids quadratic slope = 0.034, P < 0.001). While the annual non-medical use of stimulants declined over time (linear slope = 0.063, P < 0.01; quadratic slope = -0.133, P < 0.001), the same decrease was not observed for the annual non-medical use of prescription opioids, sedatives or tranquilizers when controlling for socio-demographic and substance use behaviors at baseline. The covariates associated with the general functional growth differed across the four prescription drug classes. CONCLUSIONS: The non-medical use of prescription opioids, sedatives, stimulants and tranquilizers appears to peak during late adolescence, suggesting preventive intervention efforts should be initiated in early adolescence. The developmental course of non-medical use is not the same among all four classes of prescription drugs, suggesting that each drug class warrants individual research.
Authors: Elizabeth Austic; Sean Esteban McCabe; Sarah A Stoddard; Quyen Epstein Ngo; Carol Boyd Journal: J Addict Med Date: 2015 Sep-Oct Impact factor: 3.702
Authors: Laura M Garnier; Amelia M Arria; Kimberly M Caldeira; Kathryn B Vincent; Kevin E O'Grady; Eric D Wish Journal: Am J Drug Alcohol Abuse Date: 2009 Impact factor: 3.829
Authors: John E Schulenberg; Alicia C Merline; Lloyd D Johnston; Patrick M O'Malley; Jerald G Bachman; Virginia B Laetz Journal: J Drug Issues Date: 2005
Authors: Wilson M Compton; Deborah A Dawson; Kevin P Conway; Marc Brodsky; Bridget F Grant Journal: Am J Psychiatry Date: 2013-06 Impact factor: 18.112
Authors: Ekaterina V Fedorova; Sheree M Schrager; Lucy F Robinson; Alexis M Roth; Carolyn F Wong; Ellen Iverson; Stephen E Lankenau Journal: Drug Alcohol Rev Date: 2020-05-10
Authors: Timothy E Wilens; Benjamin M Isenberg; Tamar A Kaminski; Rachael M Lyons; Javier Quintero Journal: Curr Psychiatry Rep Date: 2018-09-17 Impact factor: 5.285
Authors: Elizabeth J D'Amico; Jordan P Davis; Joan S Tucker; Rachana Seelam; Bradley D Stein Journal: Addict Behav Date: 2020-10-07 Impact factor: 3.913
Authors: Valerie S Harder; Susan E Varni; Kimberly A Murray; Timothy B Plante; Andrea C Villanti; Daniel L Wolfson; Sanchit Maruti; Kathleen M Fairfield Journal: Int J Drug Policy Date: 2021-06-06
Authors: Henry N Young; Farah Pathan; Jaxk H Reeves; Kristen N Knight; FuNing Chen; Elizabeth D Cox; Megan A Moreno Journal: J Am Coll Health Date: 2019-10-29
Authors: Justin Jager; Katherine M Keyes; Daye Son; Deb Kloska; Megan E Patrick; John E Schulenberg Journal: Drug Alcohol Depend Date: 2021-06-25 Impact factor: 4.852